SEC Form 4 · accession 0001193125-26-333136
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David-Alexandre C Gros
Officer — Chief Executive Officer · Director
Period of report
Jul 31, 2026
Accepted (ET)
Aug 4, 2026 · 5:22 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001404281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 31, 2026 | A | 354,454 | $0.00 | A | 363,454 | D | |
| Common Stock | Jul 31, 2026 | F | 194,791 | $3.38 | D | 168,663 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023.
- F2Represents shares withheld to pay tax withholding obligations due on the date of settlement.